Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News. $SIGA Technologies Gets Approval from UK_ for_Tecovirimat (TPOXX)
https://ih.advfn.com/stock-market/NASDAQ/siga-technologies-SIGA/stock-news/88553375/siga-technologies-receives-approval-from-uk-for-te
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the United Kingdom has approved SIGA’s oral tecovirimat (known in the U.S. as oral TPOXX) for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox in adults and children with a body weight of at least 13kg.
“We are very pleased that the UK has taken this important step in health emergency preparedness, not just for the immediate need in the current monkeypox outbreak, but for broader readiness by approving tecovirimat for treatment for a wide range of uses,” said Dr. Phil Gomez, CEO of SIGA. “As we have learned in the ongoing COVID-19 pandemic, building robust stockpiles in response to infectious disease outbreaks is of vital importance worldwide. This includes being ready to combat even more devastating bioterror threats such as smallpox.”
The same formulation of tecovirimat was approved by the U.S. Food and Drug Administration (FDA) in 2018 and by Health Canada in late 2021 under the brand name TPOXX® for the treatment of smallpox.In early 2022 SIGA also received market authorization for tecovirimat from the European Medicines Agency for the treatment of smallpox, monkeypox, cowpox, and complications from vaccinia infection.
-30-
News $SIGA Technologies Gets Approval from UK_ for_Tecovirimat (TPOXX)
https://ih.advfn.com/stock-market/NASDAQ/siga-technologies-SIGA/stock-news/88553375/siga-technologies-receives-approval-from-uk-for-te
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the United Kingdom has approved SIGA’s oral tecovirimat (known in the U.S. as oral TPOXX) for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox in adults and children with a body weight of at least 13kg.
“We are very pleased that the UK has taken this important step in health emergency preparedness, not just for the immediate need in the current monkeypox outbreak, but for broader readiness by approving tecovirimat for treatment for a wide range of uses,” said Dr. Phil Gomez, CEO of SIGA. “As we have learned in the ongoing COVID-19 pandemic, building robust stockpiles in response to infectious disease outbreaks is of vital importance worldwide. This includes being ready to combat even more devastating bioterror threats such as smallpox.”
The same formulation of tecovirimat was approved by the U.S. Food and Drug Administration (FDA) in 2018 and by Health Canada in late 2021 under the brand name TPOXX® for the treatment of smallpox. In early 2022 SIGA also received market authorization for tecovirimat from the European Medicines Agency for the treatment of smallpox, monkeypox, cowpox, and complications from vaccinia infection.
News SIGA Technologies Gets Approval from UK_ for_Tecovirimat (TPOXX)
https://ih.advfn.com/stock-market/NASDAQ/siga-technologies-SIGA/stock-news/88553375/siga-technologies-receives-approval-from-uk-for-te
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the United Kingdom has approved SIGA’s oral tecovirimat (known in the U.S. as oral TPOXX) for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox in adults and children with a body weight of at least 13kg.
“We are very pleased that the UK has taken this important step in health emergency preparedness, not just for the immediate need in the current monkeypox outbreak, but for broader readiness by approving tecovirimat for treatment for a wide range of uses,” said Dr. Phil Gomez, CEO of SIGA. “As we have learned in the ongoing COVID-19 pandemic, building robust stockpiles in response to infectious disease outbreaks is of vital importance worldwide. This includes being ready to combat even more devastating bioterror threats such as smallpox.”
The same formulation of tecovirimat was approved by the U.S. Food and Drug Administration (FDA) in 2018 and by Health Canada in late 2021 under the brand name TPOXX® for the treatment of smallpox. In early 2022 SIGA also received market authorization for tecovirimat from the European Medicines Agency for the treatment of smallpox, monkeypox, cowpox, and complications from vaccinia infection.
$SIGA
$SIGA TPOXX both prevents and treats monkeypox_as_used_by_clinicians. No contraindications.
FDA approved.
CDC approval for use by clinicians: CDC EA-IND protocol allows the use of tecovirimat for primary or early empiric treatment of non-variola orthopoxvirus infections, including monkeypox, in adults and children of all ages.
SIGA CSO Dr. Hruby: "Our drug TPOXX will stop further progression of the disease and then allow your natural immune system to kick in and eradicate the (monkeypox) virus.”
Hruby: "We protected virtually every animal we treated when infected with a pox virus. [...] It is approved in Europe for treatment of all orthopoxviruses."
https://www.contagionlive.com/view/a-potential-monkeypox-therapy-
"The drug traps the virus within the infected cell so it can't spread, but it still lets the immune system react to the viral antigens attacking the body," Hruby explained.
https://www.euronews.com/next/2022/05/20/monkeypox-outbreak-drugmaker-siga-says-eu-authorities-seeking-to-stockpile-its-smallpox-an
(1) Genus Orthopoxvirus includes Abatino macacapox virus, Akhmeta virus, Alaskapox virus, Camelpox virus, Cowpox virus, Ectromelia virus, Monkeypox virus, Raccoonpox virus, Skunkpox virus, Taterapox virus, Vaccinia virus, †Variola virus (smallpox), Volepox virus. [Wikipedia]
-The only people ineligible for tecovirimat treatment under the EA-IND include:
1) Patients (or their legally authorized representatives) who are unwilling to sign an informed consent and refuse tecovirimat treatment
2) Patients with known allergy to tecovirimat and/or excipients of tecovirimat
https://www.cdc.gov/poxvirus/monkeypox/clinicians/Tecovirimat.html
$SIGA
Dennis E. Hruby, Ph.D. - SIGA: Human BioArmor
"Dennis Hruby, Ph.D. is a distinguished scientist with more than 25 years of experience in poxviruses, virology, and anti-infective research. Dr. Hruby currently serves as Executive Vice President and Chief Scientific Officer, having served as SIGA's Chief Scientific Officer since 2000."
Notably, TPOXX is both a preventative-and-a-treatment-for-monkeypox, as employed-by-clinicians.
$SIGA
CSO Dr. Hruby: "Our drug (TPOXX) will stop_further_progression_of_the_disease_and_then_allow your natural immune system to kick in and eradicate the (monkeypox) virus.”
"The drug traps the virus within the infected cell so it can't spread, but it still lets the immune system react to the viral antigens attacking the body," Hruby explained.
https://www.euronews.com/next/2022/05/20/monkeypox-outbreak-drugmaker-siga-says-eu-authorities-seeking-to-stockpile-its-smallpox-an
TPOXX treats and defeats all Orthopoxviruses
Hruby: "We protected virtually every animal we treated when infected with a pox virus. [...] It is approved in Europe for treatment of all orthopoxviruses." (1)
https://www.contagionlive.com/view/a-potential-monkeypox-therapy-
(1) Genus Orthopoxvirus includes Abatino macacapox virus, Akhmeta virus, Alaskapox virus, Camelpox virus, Cowpox virus, Ectromelia virus, Monkeypox virus, Raccoonpox virus, Skunkpox virus, Taterapox virus, Vaccinia virus, †Variola virus (smallpox), Volepox virus. [Wikipedia]
CDC seal of approval for use by clinicians: CDC EA-IND protocol allows the use of tecovirimat for primary or early empiric treatment of non-variola orthopoxvirus infections, including monkeypox, in adults and children of all ages.
-The only people ineligible for tecovirimat treatment under the EA-IND include:
1) Patients (or their legally authorized representatives) who are unwilling to sign an informed consent and refuse tecovirimat treatment
2) Patients with known allergy to tecovirimat and/or excipients of tecovirimat
https://www.cdc.gov/poxvirus/monkeypox/clinicians/Tecovirimat.html
(i.e., very few)
https://www.drugs.com/search.php?searchterm=TPOXX&a=1
No warnings or contraindications reported.
$SIGA
Dennis E. Hruby, Ph.D. - SIGA: Human BioArmor
"Dennis Hruby, Ph.D. is a distinguished scientist with more than 25 years of experience in poxviruses, virology, and anti-infective research. Dr. Hruby currently serves as Executive Vice President and Chief Scientific Officer, having served as SIGA's Chief Scientific Officer since 2000."
SIGA partner Meridian Medical Tech was purchased_by_Altaris_Capital_Partners_from_Pfizer for the sum of US$50M. Altaris is a healthcare investment firm managing ~US$6B in equity capital. See current portfolio.
Dec 31, 2021
https://www.marketscreener.com/quote/stock/PFIZER-INC-23365019/news/Altaris-Capital-Partners-LLC-completed-the-acquisition-of-Meridian-Medical-Technologies-Inc-from-37829929/
June 3, 2019
https://siga.gcs-web.com/news-releases/news-release-details/siga-announces-tpoxxr-promotion-agreement-meridian-medical
https://altariscap.com/
$SIGA
$SIGA
$SIMPQ Phenomenal run; one for the books.
June 10, 2022 interview w/CSO Dr. Hruby. The information he provides gives support to "wonder drug" status for TPOXX.
https://www.contagionlive.com/view/a-potential-monkeypox-therapy-
"We saw no severe adverse events in clinical trials with humans. [...] We've seen nothing that would give us the safety signal.There are no contraindications." (FDA, CDC & EMA [European Medical Agency concur.])
"And we can give the drug quite late in the progression (after pustulent lesions form after 21 days) of the disease and still protect. (ed. Bava vacccine - only 1-4 days protection from virus.)
"[T]herapy is an oral drug. You take three capsules twice day for 14 days. We also have the IV (intravenous) formulation of this drug approved in recently in the U.S."
Dr. Hruby is Executive VP and Chief Scientific Officer of SIGA Technologies, Inc.. He has served as SIGA's CSO since 2000.
$SIGA
1st "wonder drug" was Aspirin. Add TPOXX® to_that_coveted_list.
$SIGA
Mayo Clinic weighs in on BAVA_injectable_vaccine. Problematic may be a gross understatement.(US: Jynneos/ EU: Imvanex).
Bava vaccine (US: Jynneos/ EU: Imvanex)
https://www.mayoclinic.org/drugs-supplements/smallpox-monkeypox-vaccine-live-non-replicating-subcutaneous-route/side-effects/drg-20473664?p=1
Feel lucky?
-Bava vaccine (US: Jynneos/ EU: Imvanex). "Appropriate studies have not been performed on the relationship of age to the effects of smallpox monkeypox vaccine, live non-replicating, in the pediatric population. Safety and efficacy have not been established."
-Bava vaccine (US: Jynneos/ EU: Imvanex), "This vaccine may not protect everyone who receives it."
-Bava vaccine (US: Jynneos/ EU: Imvanex). "Appropriate studies have not been performed on the relationship of age to the effects of smallpox monkeypox vaccine, live non-replicating in the elderly 65 years of age and older. Safety and efficacy have not been established."
-Bava vaccine (US: Jynneos/ EU: Imvanex). "There are no adequate studies in women for determining infant risk when using this medication during breastfeeding."
-Bava vaccine (US: Jynneos/ EU: Imvanex) "This vaccine may cause a serious allergic reaction, including anaphylaxis, which can be life-threatening and requires immediate medical attention. Call your doctor right away if you have a rash, itching, hoarseness, trouble breathing, trouble swallowing, or any swelling of your hands, face, or mouth after you receive the vaccine.
-Bava vaccine (US: Jynneos/ EU: Imvanex) known side effects: "Chills, cough, difficulty with swallowing, dizziness, fast heartbeat, hives, itching, rash, puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue, tightness in the chest, troubled breathing, unusual tiredness or weakness, bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site, headache, muscle pai, nausea."
End quote
--------------------------------------------------------------------------------------------------------
$SIGA
$SIGA TPOXX® is the only safe_effective_approved treatment_for_monkeypox.
No other drug shares that distinction.
"I love monopolies" -Warren Buffett
$SIGA TPOXX® is the only safe&effective&approved treatment_for_monkeypox.
No other pharmaceutical drug shares that distinction.
"I love monopolies" -Warren Buffett
$SIGA TPOXX® is the only safe&effective&approved treatment_for_monkeypox.
No other pharmaceutical drug shares that distinction.
If not TPOXX, what then? There_is_NO_other_Safe&Effective_treatment. End_of_story.
$SIGA
$AUVI O/S12.96M FL:7.32M News_of_large_multiunit_Medline_order.
Applied UV Announces MedLine Places Follow-On Order
July 5, 2022 08:00AM EDT
Business Wire
Continued Demand Due to Centers for Medicare & Medicaid Services Policy
Strongest Sales Channel in Company History
https://ih.advfn.com/stock-market/NASDAQ/applied-uv-AUVI/stock-news/88520358/applied-uv-announces-medline-places-follow-on-orde
John F. Andrews CEO/DIR of Applied UV, Inc. since April 8, 2022 is a major player and one of the best CEO's in the game. Stunning record of success in private and public companies alike. Mr. Andrews is an in-demand executive and chose to lead & guide smallcap AUVI. That move in itself speaks volumes. He refers to AUVI's patented NASA-developed highly advanced 99.99% air purification technologies as "Best in Class."
$AUVI O/S12.96M FL:7.32M News_of_large_multiunit_Medline_order.
Applied UV Announces MedLine Places Follow-On Order
July 05 2022 - 08:00AM
Business Wire
Continued Demand Due to Centers for Medicare & Medicaid Services Policy
Strongest Sales Channel in Company History
https://ih.advfn.com/stock-market/NASDAQ/applied-uv-AUVI/stock-news/88520358/applied-uv-announces-medline-places-follow-on-orde
John F. Andrews CEO/DIR of Applied UV, Inc since April 8, 2022 is a major player and one of the best CEO's in the game. Stunning record of success in private and public companies alike. J. F. Andrews chose to lead and guide smallcap AUVI. That move in itself speaks volumes. He's called AUVI's patented NASA-developed purification technologies "Best in Class."
$AUVI News CMS_funding_big_catalyst_in_large_Medline_multiunit_orders
Continued Demand Due to Centers for Medicare & Medicaid Services Policy
Strongest Sales Channel in Company History
https://www.businesswire.com/news/home/20220705005112/en/
$AUVI News CMS_funding_big_catalyst_in_large_Medline_multiunit_orders
MOUNT VERNON, N.Y.--(BUSINESS WIRE)--Applied UV, Inc. (NasdaqCM: AUVI) (“Applied UV” or the “Company”), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light (“UVC”) for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announces MedLine, its exclusive North American Scientific Air Management healthcare distribution partner, has placed a large multi-unit follow-on order for its patented S200 mobile air purification system.
"The follow-on order for our mobile S200 air purification is in further support of the Centers for Medicare and Medicaid Services (CMS) Policy announced earlier in the year to ease visitation in Long-term Care facilities. Under the CMS policy guidance, it provides funding available for long-term care providers looking to make air quality upgrades to their facilities to reduce the spread of COVID-19.
Continued Demand Due to Centers for Medicare & Medicaid Services Policy
Strongest Sales Channel in Company History
https://www.businesswire.com/news/home/20220705005112/en/
$AUVI News CMS_funding_huge_catalyst_in_large_Medline_multiunit_orders.
MOUNT VERNON, N.Y.--(BUSINESS WIRE)--Applied UV, Inc. (NasdaqCM: AUVI) (“Applied UV” or the “Company”), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light (“UVC”) for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announces MedLine, its exclusive North American Scientific Air Management healthcare distribution partner, has placed a large multi-unit follow-on order for its patented S200 mobile air purification system.
"The follow-on order for our mobile S200 air purification is in further support of the Centers for Medicare and Medicaid Services (CMS) Policy announced earlier in the year to ease visitation in Long-term Care facilities. Under the CMS policy guidance, it provides funding available for long-term care providers looking to make air quality upgrades to their facilities to reduce the spread of COVID-19.
Continued Demand Due to Centers for Medicare & Medicaid Services Policy
Strongest Sales Channel in Company History
https://www.businesswire.com/news/home/20220705005112/en/
News. 'Strongest Sales Channel in Company History' CMS_policy_guidance_bullish_for_sales (i.e., CMS availing funding).
MOUNT VERNON, N.Y.--(BUSINESS WIRE)--Applied UV, Inc. (NasdaqCM: AUVI) (“Applied UV” or the “Company”), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light (“UVC”) for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announces MedLine, its exclusive North American Scientific Air Management healthcare distribution partner, has placed a large multi-unit follow-on order for its patented S200 mobile air purification system.
"The follow-on order for our mobile S200 air purification is in further support of the Centers for Medicare and Medicaid Services (CMS) Policy announced earlier in the year to ease visitation in Long-term Care facilities. Under the CMS policy guidance, it provides funding available for long-term care providers looking to make air quality upgrades to their facilities to reduce the spread of COVID-19.[/u
https://www.businesswire.com/news/home/20220705005112/en/
$AUVI
$AUVI When a Big League Exec_joins smallcap_as_CEO/Dir_you_know_big_things_are_afoot. Major player J.F. Andrews joined Applied UV, Inc. [AUVI] (Best in Class FDA approved, NASA-developed technology) on 8Apr2022. Contracts keep abuzzing in. Fuse lit for major leg up.
[Applied UV, Inc., O/S 12.96M Float 7.2M, Cash $7.1M, Debt $0.2M Q1 2022] $2.19/sh presently.
J.F. Andrews bio
-Chief Information Officer & Senior VP at Rail giant $CSX Corp. and President of sub CSX Technology, Inc.
CSX Andrews cut $500M from operating expenses "through his visionary and portfolio technology projects. As CIO, he received several industry awards to include CIO of the Year from Information Week and Top Industry Visionary from Computerworld."
-"... Mr. Andrews served as a member of the Board of Directors and as Head of Sales of ShipXpress Inc., a SAAS based logistics software company. In this role, he was a key principal in the process of the sale of the company to General Electric ($GE) [for an undisclosed sum] on September 1, 2016."
SEC Form 10-K
-"Duos Technologies Group, Inc. (Nasdaq:$DUOT) Appoints John F. Andrews as Chief Operating Officer and Executive Vice President, Effective April 3, 2017"
"Mr. Andrews is a senior executive with a demonstrated record of success in achieving revenue, profit and business goals in start-up and large corporate environments for both public and private companies. His business experience has spanned multiple industries including telecommunications, healthcare, transportation, and information technology."
-Co-founder & CEO John F. Andrews of Giga Information Group, Inc. (Nasdaq: GIGA), Cambridge, Mass. Revenues US$69.8 million, 275 employees. Andrews spearheads the sale of Giga to Forrester Group (Nasdaq: $FORR) for US$60 million
-CEO of TrekSecure, Inc. (current)
https://www.treksecure.com/
-From 2021 to April of 2022 Mr. Andrews served as Chief Executive Officer of Trinity IT Services LLC, which is an IT services company in Jacksonville Florida. At Trinity IT Mr. Andrews successfully launched the company, signed contracts with the State of Florida, Fiserv, Mastercard, Point72, Credit Agricole and Tech Mahindra. (AUVI 8K April 8, 2022)
John F. Andrews
Chief Executive Officer & Resolution Director at EBC, Inc., Chief Executive Officer & Director at Varsity Media Group, Inc., Chief Executive Officer at Evans Data Corp., Chief Operating Officer & Executive Vice President at Duos Technologies Group, Inc. and President & Chief Operating Officer of Duos Technologies, Inc. (a subsidiary of Duos Technologies Group, Inc.), Chief Information Officer & Senior VP at CSX Corp. and President for CSX Technology, Inc. (subsidiary of CSX Corp.), Chief Technology Officer of KyckGlobal, Inc., Chief Executive Officer at Giga Information Group, Inc., Director & Head-Sales at ShipXpress, Inc. and Chief Operating Officer of Girl Scout of Gateway Council, Inc
$AUVI When a Big League Exec joins smallcap_as_CEO/Dir, you know that big things are in the works. J.F. Andrews joined AUVI on April 8, 2022.
[Applied UV, Inc., O/S 12.96M Float 7.2M, Cash $7.1M, Debt $0.2M Q1 2022]
J.F. Andrews bio
-Chief Information Officer & Senior VP at Rail giant $CSX Corp. and President for CSX Technology, Inc.
CSX Andrews cut $500M from operating expenses "through his visionary and portfolio technology projects. As CIO, he received several industry awards to include CIO of the Year from Information Week and Top Industry Visionary from Computerworld."
-"... Mr. Andrews served as a member of the Board of Directors and as Head of Sales of ShipXpress Inc., a SAAS* based logistics software company. In this role, he was a key principal in the process of the sale of the company to General Electric ($GE) [for an undisclosed sum] on September 1, 2016."
SEC Form 10-K
-"Duos Technologies Group, Inc. (Nasdaq:$DUOT) Appoints John F. Andrews as Chief Operating Officer and Executive Vice President, Effective April 3, 2017"
"Mr. Andrews is a senior executive with a demonstrated record of success in achieving revenue, profit and business goals in start-up and large corporate environments for both public and private companies. His business experience has spanned multiple industries including telecommunications, healthcare, transportation and information technology."
-Co-founder & CEO John F. Andrews of Giga Information Group, Inc. (Nasdaq: GIGA), Cambridge, Mass. Revenues US$69.8 million, 275 employees. Andrews spearheads the sale of Giga to Forrester Group (Nasdaq: $FORR) for US$60 million
-CEO of TrekSecure, Inc. (current)
https://www.treksecure.com/
-From 2021 to April of 2022 Mr. Andrews served as Chief Executive Officer of Trinity IT Services LLC, which is an IT services company in Jacksonville Florida. At Trinity IT Mr. Andrews successfully launched the company, signed contracts with the State of Florida, Fiserv, Mastercard, Point72, Credit Agricole and Tech Mahindra. (AUVI 8K April 8, 2022)
John F. Andrews
Chief Executive Officer & Resolution Director at EBC, Inc., Chief Executive Officer & Director at Varsity Media Group, Inc., Chief Executive Officer at Evans Data Corp., Chief Operating Officer & Executive Vice President at Duos Technologies Group, Inc. and President & Chief Operating Officer of Duos Technologies, Inc. (a subsidiary of Duos Technologies Group, Inc.), Chief Information Officer & Senior VP at CSX Corp. and President for CSX Technology, Inc. (subsidiary of CSX Corp.), Chief Technology Officer of KyckGlobal, Inc., Chief Executive Officer at Giga Information Group, Inc., Director & Head-Sales at ShipXpress, Inc. and Chief Operating Officer of Girl Scout of Gateway Council, Inc
$AUVI O/S 12.96M Float 7.32M Cash $7.1M $0.2M debt. As of March 31. High-end NASA technology.
John F. Andrews appointed CEO of Applied UV, Inc. very recently. Revolutionary NASA-developed air purification technology eradicates 99.99% of all pathogens, viruses, fungi, pollutants et cetera. FDA approved. Contracts buzzing in, though shares are cheap right now in this punk market. Look up John F. Andrews. Stunningly successful, John F. Andrews is the "Powerhouse with the Midas Touch" for BO & Major Partnerships--who is now guiding AUVI as CEO & Director. The entrance of Andrews, who can write his own ticket, portends big things are in the works. Otherwise, an in-demand executive of his stature, expertise, and record of successes wouldn't bother with a small cap firm.
CEO & Director John F. Andews: “I am thrilled to have the opportunity of leading Applied UV at this most important time for the company as we are in position to accelerate our growth in the global air purification and pathogen elimination market. The growing market tailwinds created by the recent government initiatives, guidelines and policies surrounding improving indoor air, Applied UV’s best in class suite of air purification technologies is well suited to fill this growing global demand of cleaner in-door air and pathogen elimination. I look forward to working together with our Board of Directors, senior executives, employees, and consultants as we embark upon this journey.”
"Our balance sheet is strong with ample cash on hand to support our growth initiatives, and we just recently announced — and we just recently announced that our Board of Directors has approved a $1 million share repurchase program of our common stock in open market transactions that will remain in effect until September of this year."
https://news.alphastreet.com/applied-uv-inc-auvi-q4-2021-earnings-call-transcript/
Chief Executive Officer & Resolution Director at EBC, Inc., Chief Executive Officer & Director at Varsity Media Group, Inc., Chief Executive Officer at Evans Data Corp., Chief Operating Officer & Executive Vice President at Duos Technologies Group, Inc. and President & Chief Operating Officer of Duos Technologies, Inc. (a subsidiary of Duos Technologies Group, Inc.), Chief Information Officer & Senior VP at CSX Corp. and President for CSX Technology, Inc. (a subsidiary of $CSX Corp.), Chief Technology Officer of KyckGlobal, Inc., Chief Executive Officer at Giga Information Group, Inc., Director & Head-Sales at ShipXpress, Inc. and Chief Operating Officer of Girl Scout of Gateway Council, Inc.
$AUVI Moving. O/S 12.96M Float 7.32M. Powerhouse CEO has taken over the reins recently. Look up John F. Andrews.The entrance of Andrews, who can write his own ticket, portends big things are in the works. Otherwise, an in-demand executive of his stature, expertise, and record of successes wouldn't bother with a small cap firm.
Revolutionary NASA-developed air purification technology eradicates 99.99% of all pathogens, viruses, fungi, pollutants et cetera. FDA approved. Contracts buzzing in, shares very cheap in this punk market. John F. Andrews--the "Powerhouse with the Midas Touch" for BO & Major Partnerships--now guiding AUVI as CEO & Director.
$AUVI Fortune 300 SVP appointed CEO very recently. Revolutionary NASA-developed air purification technology eradicates 99.99% of all pathogens, viruses, fungi, pollutants et cetera (etc.). FDA approved. Contracts buzzing in, though shares are very cheap right now in this punk market. Look up John F. Andrews. Stunningly successful, John F. Andrews is the "Powerhouse with the Midas Touch" for BO & Major Partnerships--who is now guiding AUVI as CEO & Director. The entrance of Andrews, who can write his own ticket, portends big things are in the works. Otherwise, an in-demand executive of his stature, expertise, and record of successes wouldn't bother with a small cap firm.
Newswatch on.
Per Marketwatch:
Shares Outstanding
12.96M
Public Float
7.32M
$AUVI Newswatch. Fortune 300 SVP appointed CEO recently. Revolutionary NASA-developed air purification technology 99.99% eradication of all pathogens, viruses, fungi, pollutants et cetera. FDA approved. Contracts! Stock is uber cheap now. Look up John F. Andrews. Powerhouse CEO now guiding AUVI.
$AUVI Newswatch. Fortune 300 SVP appointed CEO recently.
Phexxi: Lactic acid, citric acid & potassium bitartrate. Common chemicals, non-exclusive. Invites copycats.
Generic name: citric acid, lactic acid, and potassium bitartrate
Brand name: Phexxi
Dosage form: vaginal gel (1%-1.8%-0.4%)
https://www.drugs.com/mtm/citric-acid-lactic-acid-and-potassium-bitartrate.html
Tycoon Exec, ex VP/GTE, ex SVP/CIO CSX etc=>$AUVI-CEO/DIr-8Apr22.
John F. Andrews appointed CEO & Director of Applied UV, Inc. 08 April 2022
Powerhouse John F. Andrews joining Applied UV, Inc., as CEO/Director signals tremendous growth is at hand. With a business background as deep and successful as his, the highly talented and dynamic John Andrew, an in-demand business tycoon, who can write his own ticket, would only have accepted the offer if AUVI air purification technology, developed by NASA, were top of the line and the opportunity for immense rewards irresistible. Andrews refers to the game-changing suite of AUVI products as "best in class."
Andrews' proven modus operandi: Growth --> BO / Major Partnerships courtesy of the Andrews' Midas Touch.
1) March 22, 2017 "Duos Technologies Group, Inc. (Nasdaq: DUOT) Appoints John F. Andrews as Chief Operating Officer and Executive Vice President, Effective April 3, 2017"
https://www.marketscreener.com/quote/stock/DUOS-TECHNOLOGIES-GROUP-100152623/news/Duos-Technologies-Group-Inc-Appoints-John-F-Andrews-as-Chief-Operating-Officer-and-Executive-Vice-35156649/
(3 months later)
1a) June 22, 2017 Duos Technologies Becomes Member of IBM's PartnerWorld
https://finance.yahoo.com/news/duos-technologies-becomes-member-ibms-120000672.html
2) "... Mr. Andrews served as a member of the Board of Directors and as Head of Sales of ShipXpress Inc., a SAAS* based logistics software company. In this role, he was a key principal in the process of the sale of the company to General Electric ($GE) [for an undisclosed sum] on September 1, 2016."
SEC Form 8-K ShipXpress
*SAAS (software as a service [Web based software])
-2a) August 30, 2016: GE Transportation (NYSE: $GE) [...] announced its acquisition of ShipXpress, a top provider of cloud-based software solutions that enable transportation, industrial, and commodities businesses to efficiently operate with supply chain partners.
https://www.ge.com/news/press-releases/ge-acquires-top-supply-chain-software-provider-shipxpress-expand-digital-rail
3) January 2003: Co-founder & CEO John F. Andrews of Giga Information Group, Inc. (Nasdaq: GIGA), Cambridge, Mass. Revenues US$69.8 million, 275 employees. Andrews spearheads the sale of Giga to Forrester Group (Nasdaq: $FORR) for US$60 million https://www.wsj.com/articles/SB1043162630331757384
4) From 2021 to April of 2022 Mr. Andrews served as Chief Executive Officer of Trinity IT Services LLC, which is an IT services company in Jacksonville Florida. At Trinity IT Mr. Andrews successfully launched the company, signed contracts with the State of Florida, Fiserv, Mastercard, Point72, Credit Agricole and Tech Mahindra. (AUVI 8K April 8, 2022)
https://fintel.io/doc/sec-applied-uv-inc-1811109-8k-2022-april-08-19090-6650
5) CEO of TrekSecure, Inc. (current)
https://www.treksecure.com/
6) 1997 Chief Information Officer & Senior VP at Rail giant CSX Corp. and President for CSX Technology, Inc.
Andrews' knowledge and expertise along with a talent for innovative leadership saves CSX Corp. "$10M in yearly labor and equipment costs." [US$18M adjusted for 2022] [$CSX Corp. Current market cap $62.1B]
https://www.deepdyve.com/lp/association-for-computing-machinery/peopleware-emerging-roles-and-responsibilities-an-interview-with-john-a2zTrEMhL2
Chief Executive Officer & Resolution Director at EBC, Inc., Chief Executive Officer & Director at Varsity Media Group, Inc., Chief Executive Officer at Evans Data Corp., Chief Operating Officer & Executive Vice President at Duos Technologies Group, Inc. and President & Chief Operating Officer of Duos Technologies, Inc. (a subsidiary of Duos Technologies Group, Inc.), Chief Information Officer & Senior VP at CSX Corp. and President for CSX Technology, Inc. (a subsidiary ofCSX Corp.), Chief Technology Officer of KyckGlobal, Inc., Chief Executive Officer at Giga Information Group, Inc., Director & Head-Sales at ShipXpress, Inc. and Chief Operating Officer of Girl Scout of Gateway Council, Inc.
Tycoon Exec, ex VP/GTE, ex SVP/CIO CSX etc=>$AUVI-CEO/DIr-8Apr22.
John F. Andrews appointed CEO & Director of Applied UV, Inc. 08 April 2022
Powerhouse J.F. Andrews joining Applied UV, Inc, as CEO signals tremendous growth is at hand. With a business background as deep and successful as his, the highly talented John Andrew, a business tycoon, would not have accepted the offer unless AUVI air purification technology, developed by NASA, were top of the line anthe opportunity for immense rewards were irresistible. Andrews refers to the impressive suite of game-changing products as "best in class."
Andrews' proven M.O.- Growth->BO/Major Partnerships.The Midas Touch
1) March 22, 2017 "Duos Technologies Group, Inc. (Nasdaq: DUOT) Appoints John F. Andrews as Chief Operating Officer and Executive Vice President, Effective April 3, 2017"
https://www.marketscreener.com/quote/stock/DUOS-TECHNOLOGIES-GROUP-100152623/news/Duos-Technologies-Group-Inc-Appoints-John-F-Andrews-as-Chief-Operating-Officer-and-Executive-Vice-35156649/
(3 months later)
1a) June 22, 2017 Duos Technologies Becomes Member of IBM's PartnerWorld
https://finance.yahoo.com/news/duos-technologies-becomes-member-ibms-120000672.html
2) "... Mr. Andrews served as a member of the Board of Directors and as Head of Sales of ShipXpress Inc., a SAAS* based logistics software company. In this role, he was a key principal in the process of the sale of the company to General Electric ($GE) [for an undisclosed sum] on September 1, 2016."
SEC Form 8-K ShipXpress
*SAAS (software as a service [Web based software])
-2a) August 30, 2016: GE Transportation (NYSE: $GE) [...] announced its acquisition of ShipXpress, a top provider of cloud-based software solutions that enable transportation, industrial, and commodities businesses to efficiently operate with supply chain partners.
https://www.ge.com/news/press-releases/ge-acquires-top-supply-chain-software-provider-shipxpress-expand-digital-rail
3) January 2003: Co-founder & CEO John F. Andrews of Giga Information Group, Inc. (Nasdaq: GIGA), Cambridge, Mass. Revenues US$69.8 million, 275 employees. Andrews spearheads the sale of Giga to Forrester Group (Nasdaq: $FORR) for US$60 million https://www.wsj.com/articles/SB1043162630331757384
4) From 2021 to April of 2022 Mr. Andrews served as Chief Executive Officer of Trinity IT Services LLC, which is an IT services company in Jacksonville Florida. At Trinity IT Mr. Andrews successfully launched the company, signed contracts with the State of Florida, Fiserv, Mastercard, Point72, Credit Agricole and Tech Mahindra. (AUVI 8K April 8, 2022)
https://fintel.io/doc/sec-applied-uv-inc-1811109-8k-2022-april-08-19090-6650
5) CEO of TrekSecure, Inc. (current)
https://www.treksecure.com/
6) 1997 Chief Information Officer & Senior VP at Rail giant CSX Corp. and President for CSX Technology, Inc.
Andrews' knowledge and expertise along with a talent for innovative leadership saves CSX Corp. "$10M in yearly labor and equipment costs." [US$18M adjusted for 2022] [$CSX Corp. Current market cap $62.1B]
https://www.deepdyve.com/lp/association-for-computing-machinery/peopleware-emerging-roles-and-responsibilities-an-interview-with-john-a2zTrEMhL2
Chief Executive Officer & Resolution Director at EBC, Inc., Chief Executive Officer & Director at Varsity Media Group, Inc., Chief Executive Officer at Evans Data Corp., Chief Operating Officer & Executive Vice President at Duos Technologies Group, Inc. and President & Chief Operating Officer of Duos Technologies, Inc. (a subsidiary of Duos Technologies Group, Inc.), Chief Information Officer & Senior VP at CSX Corp. and President for CSX Technology, Inc. (a subsidiary ofCSX Corp.), Chief Technology Officer of KyckGlobal, Inc., Chief Executive Officer at Giga Information Group, Inc., Director & Head-Sales at ShipXpress, Inc. and Chief Operating Officer of Girl Scout of Gateway Council, Inc.
A record of cost-savings. At $CSX Andrews_cut_$500M_from_operating expenses "through_his_ visionary and portfolio technology projects. As CIO, he received several industry awards to include CIO of the Year from Information Week and Top Industry Visionary from Computerworld."
$HUSA Did they strike oil in Colombia?
Aegis Capital initiates coverage Applied UV Buy PT $8.
https://www.marketbeat.com/r/178360
$AUVI Aegis Capital analyst Nathan Weinstein initiates coverage on Applied UV with a Buy rating and announces Price Target of $8. (June 27, 2022)
That should attract more eyeballs to this one.
Tailwind:Recent_government_initiatives_guidelines_and_policies_about_improving_indoor_air_ and_Applied UV’s best in class suite of air purification technologies is well suited to fill this growing global demand of cleaner in-door air and pathogen elimination.
EO & Director John F. Andews: “I am thrilled to have the opportunity of leading Applied UV at this most important time for the company as we are in position to accelerate our growth in the global air purification and pathogen elimination market. The growing market tailwinds created by the recent government initiatives, guidelines and policies surrounding improving indoor air, Applied UV’s best in class suite of air purification technologies is well suited to fill this growing global demand of cleaner in-door air and pathogen elimination. I look forward to working together with our Board of Directors, senior executives, employees, and consultants as we embark upon this journey.”
CEO: Applied_UV’s_best_in_class_suite_of air_purification_technologies_is well_suited_ to_fill_this_growing_global_demand _of cleaner in-door air and pathogen elimination."
CEO & Director John F. Andews: “I am thrilled to have the opportunity of leading Applied UV at this most important time for the company as we are in position to accelerate our growth in the global air purification and pathogen elimination market. The growing market tailwinds created by the recent government initiatives, guidelines and policies surrounding improving indoor air, Applied UV’s best in class suite of air purification technologies is well suited to fill this growing global demand of cleaner in-door air and pathogen elimination. I look forward to working together with our Board of Directors, senior executives, employees, and consultants as we embark upon this journey.”
Buckle up! CEO: We_are_in_ a_position_to_accelerate_our_growth _in_the_global_air purification_and_pathogen_elimination_market.
CEO & Director John F. Andews: “I am thrilled to have the opportunity of leading Applied UV at this most important time for the company as we are in position to accelerate our growth in the global air purification and pathogen elimination market. The growing market tailwinds created by the recent government initiatives, guidelines and policies surrounding improving indoor air, Applied UV’s best in class suite of air purification technologies is well suited to fill this growing global demand of cleaner in-door air and pathogen elimination. I look forward to working together with our Board of Directors, senior executives, employees, and consultants as we embark upon this journey.”
Andrews' proven M.O.- Growth->BO/Major Partnerships.The Midas Touch:Examples..
[Next up Applied UV, Inc.]
John F. Andrews, CEO & Director of Applied UV, Inc. (As of April 8th, 2022)
1) March 22, 2017 "Duos Technologies Group, Inc. (Nasdaq: DUOT) Appoints John F. Andrews as Chief Operating Officer and Executive Vice President, Effective April 3, 2017"
https://www.marketscreener.com/quote/stock/DUOS-TECHNOLOGIES-GROUP-100152623/news/Duos-Technologies-Group-Inc-Appoints-John-F-Andrews-as-Chief-Operating-Officer-and-Executive-Vice-35156649/
(3 months later)
1a) June 22, 2017 Duos Technologies Becomes Member of IBM's PartnerWorld
https://finance.yahoo.com/news/duos-technologies-becomes-member-ibms-120000672.html
2) "... Mr. Andrews served as a member of the Board of Directors and as Head of Sales of ShipXpress Inc., a SAAS* based logistics software company. In this role, he was a key principal in the process of the sale of the company to General Electric ($GE) [for an undisclosed sum] on September 1, 2016."
SEC Form 8-K ShipXpress
*SAAS (software as a service [Web based software])
-2a) August 30, 2016: GE Transportation (NYSE: $GE) [...] announced its acquisition of ShipXpress, a top provider of cloud-based software solutions that enable transportation, industrial, and commodities businesses to efficiently operate with supply chain partners.
https://www.ge.com/news/press-releases/ge-acquires-top-supply-chain-software-provider-shipxpress-expand-digital-rail
3) January 2003: Co-founder & CEO John F. Andrews of Giga Information Group, Inc. (Nasdaq: GIGA), Cambridge, Mass. Revenues US$69.8 million, 275 employees. Andrews spearheads the sale of Giga to Forrester Group (Nasdaq: $FORR) for US$60 million https://www.wsj.com/articles/SB1043162630331757384
4) From 2021 to April of 2022 Mr. Andrews served as Chief Executive Officer of Trinity IT Services LLC, which is an IT services company in Jacksonville Florida. At Trinity IT Mr. Andrews successfully launched the company, signed contracts with the State of Florida, Fiserv, Mastercard, Point72, Credit Agricole and Tech Mahindra. (AUVI 8K April 8, 2022)
https://fintel.io/doc/sec-applied-uv-inc-1811109-8k-2022-april-08-19090-6650
5) CEO of TrekSecure, Inc. (current)
https://www.treksecure.com/
6) 1997 Chief Information Officer & Senior VP at Rail giant CSX Corp. and President for CSX Technology, Inc.
Andrews' knowledge and expertise along with a talent for innovative leadership saves CSX Corp. "$10M in yearly labor and equipment costs." [US$18M adjusted for 2022] [$CSX Corp. Current market cap $62.1B]
https://www.deepdyve.com/lp/association-for-computing-machinery/peopleware-emerging-roles-and-responsibilities-an-interview-with-john-a2zTrEMhL2
$AUVI
"Levels of air purification never before possible."* Watch the video.
Video inset
https://sterilumen.com/disinfection-products/
Separate link
Subs Sterilumen & MunnWorks 100% owned by Applied UV, Inc.
https://sterilumen.com/
Disinfection Technologies
-Airocide® : The most advanced medical grade air purifiers on the market.
-Lumicide™ : Germicidal ultraviolet light in safe and simple designs.
"SteriLumen disinfection technologies kill pathogens, including the SARS-CoV-2 human coronavirus, as well as other common healthcare acquired/associated infections (HAIs) like C. diff, E. coli, MRSA and H1N1.
Independent laboratory testing from CUBRC, a biosafety level 3 lab (BSL-3), confirmed 99.9% viral inactivation of SARS-COV-2 in just 5 minutes. In addition, ResInnova Laboratories, an IAC certified testing organization and biosafety level 2 (BSL-2), tested both the SteriLumen Ribbon and SteriLumen Drain units against C. diff, MRSA, E. coli, H1N1 and OC-43 resulting in greater than 99.9% viral inactivation."
$AUVI